We have located links that may give you full text access.
Niosomes based formulation containing tenoxicam: A newer solution for the rheumatic diseases.
Annales Pharmaceutiques Françaises 2023 November 2
OBJECTIVE: According to the World Health Organization (WHO), 29 million people worldwide will suffer from rheumatic diseases by 2022. This investigation aimed to explore the potential of non-ionic surfactant based niosomal vesicles encapsulating tenoxicam (TN; anti- rheumatic drug) for the treatment of rheumatic diseases.
MATERIAL AND METHODS: Mechanical dispersion technique with controlled pressure was employed to prepare different niosomal formulations. The effects of different ratios of surfactant (span-60), lipid, and sodium deoxycholate on noisome's physicochemical properties have been examined. Moreover, inhibition of TNF-α in lipopolysaccharide-activated cultured Human leukemia monocytic (THP-1) cells were demonstrated to assess the in vitro inflammation profile. Finally, the optimized niosomal formulation (TN3) was prepared in gel matrix consist of carbopol 934 (termed as TN34) and stability was also tested at 4±2 ᵒC, 25±2 ᵒC, 37±2 ᵒC and 45±2 ᵒC for 6 months.
RESULTS: The optimized niosomal formulation exhibited a small vesicle size (165±14 nm) and high drug encapsulation (79.64±1.5%). Niosomal gel formulation TN34 showed pH (6.7), viscosity (6810± 3.34 cps), spreadability (19.11±1.87 gm.cm/sec) and also displayed sustained release pattern of drug release (98.16±0.07 % TN released from gel matrix in 24 h) in vitro release study. TN34 exhibited substantial anti-inflammatory response, with ∼75% inhibition of TNF-α in 48 h. Stability investigation revealed that refrigerator temperature is most suitable for the storage of niosomal gel.
CONCLUSION: Topical niosomal formulation displayed promising potential in the treatment of rheumatic diseases.
MATERIAL AND METHODS: Mechanical dispersion technique with controlled pressure was employed to prepare different niosomal formulations. The effects of different ratios of surfactant (span-60), lipid, and sodium deoxycholate on noisome's physicochemical properties have been examined. Moreover, inhibition of TNF-α in lipopolysaccharide-activated cultured Human leukemia monocytic (THP-1) cells were demonstrated to assess the in vitro inflammation profile. Finally, the optimized niosomal formulation (TN3) was prepared in gel matrix consist of carbopol 934 (termed as TN34) and stability was also tested at 4±2 ᵒC, 25±2 ᵒC, 37±2 ᵒC and 45±2 ᵒC for 6 months.
RESULTS: The optimized niosomal formulation exhibited a small vesicle size (165±14 nm) and high drug encapsulation (79.64±1.5%). Niosomal gel formulation TN34 showed pH (6.7), viscosity (6810± 3.34 cps), spreadability (19.11±1.87 gm.cm/sec) and also displayed sustained release pattern of drug release (98.16±0.07 % TN released from gel matrix in 24 h) in vitro release study. TN34 exhibited substantial anti-inflammatory response, with ∼75% inhibition of TNF-α in 48 h. Stability investigation revealed that refrigerator temperature is most suitable for the storage of niosomal gel.
CONCLUSION: Topical niosomal formulation displayed promising potential in the treatment of rheumatic diseases.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app